$SSY
SUNLINK HEALTH SYSTEMS INC

2018 Q4 Form 10-Q Financial Statement

#000156459019002949 Filed on February 14, 2019

View on sec.gov

Income Statement

Concept 2018 Q4 2017 Q4 2017
Revenue $14.22M $13.88M $53.29M
YoY Change 2.49% -2.64% -15.99%
Cost Of Revenue $9.172M $662.0K $19.92M
YoY Change 1285.5% -7.15% 513.21%
Gross Profit $13.19M $13.22M $33.37M
YoY Change -0.23% -2.41% -44.55%
Gross Profit Margin 92.71% 95.23% 62.62%
Selling, General & Admin $11.36M $4.240M $28.99M
YoY Change 168.02% -41.27% -25.25%
% of Gross Profit 86.18% 32.08% 86.87%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $689.0K $280.0K $1.987M
YoY Change 146.07% -40.43% -18.43%
% of Gross Profit 5.23% 2.12% 5.95%
Operating Expenses $14.05M $4.300M $57.36M
YoY Change 226.65% -51.14% 17.8%
Operating Profit -$134.0K -$80.00K -$4.510M
YoY Change 67.5% -385.71% -30.86%
Interest Expense $60.00K $119.0K $635.0K
YoY Change -49.58% -24.2% -24.67%
% of Operating Profit
Other Income/Expense, Net $480.0K
YoY Change -56.76%
Pretax Income $258.0K $503.0K -$2.471M
YoY Change -48.71% -80.48% -66.41%
Income Tax $0.00 -$296.0K -$512.0K
% Of Pretax Income 0.0% -58.85%
Net Earnings $305.0K $726.0K $2.688M
YoY Change -57.99% -76.57% -119.09%
Net Earnings / Revenue 2.14% 5.23% 5.04%
Basic Earnings Per Share $0.04 $0.08 $0.29
Diluted Earnings Per Share $0.04 $0.08 $0.29
COMMON SHARES
Basic Shares Outstanding 7.271M 8.688M 9.346M shares
Diluted Shares Outstanding 7.278M 8.758M 9.346M shares

Balance Sheet

Concept 2018 Q4 2017 Q4 2017
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.326M $3.000M $10.49M
YoY Change 10.87% -79.17% 221.8%
Cash & Equivalents $3.326M $2.959M $10.49M
Short-Term Investments
Other Short-Term Assets $2.407M $4.100M $4.062M
YoY Change -41.29% 51.85% -30.6%
Inventory $1.953M $2.149M $2.159M
Prepaid Expenses
Receivables $5.508M $6.400M $5.906M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $13.19M $15.53M $22.62M
YoY Change -15.02% -39.96% 26.43%
LONG-TERM ASSETS
Property, Plant & Equipment $10.00M $10.55M $10.29M
YoY Change -5.18% -2.61% -20.81%
Goodwill
YoY Change
Intangibles $1.412M $1.529M
YoY Change -7.65% -41.73%
Long-Term Investments
YoY Change
Other Assets $812.0K $758.0K $838.0K
YoY Change 7.12% -12.47% -91.67%
Total Long-Term Assets $12.53M $13.13M $12.72M
YoY Change -4.57% -11.17% -51.49%
TOTAL ASSETS
Total Short-Term Assets $13.19M $15.53M $22.62M
Total Long-Term Assets $12.53M $13.13M $12.72M
Total Assets $25.73M $28.66M $35.34M
YoY Change -10.23% -29.49% -19.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.526M $1.765M $1.571M
YoY Change -13.54% -29.0% -53.67%
Accrued Expenses $642.0K $307.0K $3.375M
YoY Change 109.12% -33.41% -25.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $292.0K $263.0K $6.710M
YoY Change 11.03% -47.29% -10.21%
Total Short-Term Liabilities $5.678M $5.438M $12.31M
YoY Change 4.41% -24.19% -38.59%
LONG-TERM LIABILITIES
Long-Term Debt $2.815M $2.929M $0.00
YoY Change -3.89% -54.69% -100.0%
Other Long-Term Liabilities $221.0K $258.0K $1.329M
YoY Change -14.34% -14.57% -16.2%
Total Long-Term Liabilities $3.815M $4.016M $1.329M
YoY Change -5.0% -48.55% -70.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.678M $5.438M $12.31M
Total Long-Term Liabilities $3.815M $4.016M $1.329M
Total Liabilities $9.493M $9.454M $13.64M
YoY Change 0.41% -36.88% -44.58%
SHAREHOLDERS EQUITY
Retained Earnings $2.168M $4.785M
YoY Change -54.69% -38.41%
Common Stock $14.24M $14.75M
YoY Change -3.42% -19.49%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $16.23M $19.20M $21.69M
YoY Change
Total Liabilities & Shareholders Equity $25.73M $28.66M $35.34M
YoY Change -10.23% -29.49% -19.88%

Cashflow Statement

Concept 2018 Q4 2017 Q4 2017
OPERATING ACTIVITIES
Net Income $305.0K $726.0K $2.688M
YoY Change -57.99% -76.57% -119.09%
Depreciation, Depletion And Amortization $689.0K $280.0K $1.987M
YoY Change 146.07% -40.43% -18.43%
Cash From Operating Activities -$314.0K $40.00K -$5.610M
YoY Change -885.0% -105.56% 1216.9%
INVESTING ACTIVITIES
Capital Expenditures $232.0K $388.0K $1.630M
YoY Change -40.21% -31.21% 21.01%
Acquisitions
YoY Change
Other Investing Activities $935.0K $0.00 $20.10M
YoY Change -100.0% 95609.52%
Cash From Investing Activities $697.0K -$390.0K $18.47M
YoY Change -278.72% -108.92% -1391.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $641.0K
YoY Change
Debt Paid & Issued, Net $3.985M
YoY Change 364.99%
Cash From Financing Activities -450.0K -6.590M -5.626M
YoY Change -93.17% 218.36% 556.48%
NET CHANGE
Cash From Operating Activities -314.0K 40.00K -5.610M
Cash From Investing Activities 697.0K -390.0K 18.47M
Cash From Financing Activities -450.0K -6.590M -5.626M
Net Change In Cash -67.00K -6.940M 7.233M
YoY Change -99.03% -539.24% -366.61%
FREE CASH FLOW
Cash From Operating Activities -$314.0K $40.00K -$5.610M
Capital Expenditures $232.0K $388.0K $1.630M
Free Cash Flow -$546.0K -$348.0K -$7.240M
YoY Change 56.9% -72.9% 308.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
29995000
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20107000
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19589000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10003000
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10406000
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1412000
CY2018Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1470000
CY2018Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
305000
CY2018Q2 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
305000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
812000
CY2018Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
885000
CY2018Q4 us-gaap Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment
AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
2529000
CY2018Q2 us-gaap Assets Noncurrent Other Than Noncurrent Investments And Property Plant And Equipment
AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment
2660000
CY2018Q4 us-gaap Assets
Assets
25726000
CY2018Q2 us-gaap Assets
Assets
26176000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1526000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2407000
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2937000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
13194000
CY2018Q2 us-gaap Assets Current
AssetsCurrent
13110000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
30110000
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1239000
CY2018Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
292000
CY2018Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
255000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1914000
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1959000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
642000
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
290000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1304000
CY2018Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1108000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5678000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4851000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2815000
CY2018Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2803000
CY2018Q4 ssy Professional Liability Risks Non Current
ProfessionalLiabilityRisksNonCurrent
779000
CY2018Q2 ssy Professional Liability Risks Non Current
ProfessionalLiabilityRisksNonCurrent
996000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-2000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
144000
ssy Payments To Acquire Property Plant And Equipment Continuing Operations
PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations
694000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
243000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
138000
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3456000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
221000
CY2018Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
340000
CY2018Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3815000
CY2018Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4139000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
3493000
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
3673000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
10749000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
10947000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2168000
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2743000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-177000
CY2018Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-177000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
16233000
CY2018Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17186000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25726000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26176000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2018Q4 us-gaap Preferred Stock Share Subscriptions
PreferredStockShareSubscriptions
2000000
CY2018Q2 us-gaap Preferred Stock Share Subscriptions
PreferredStockShareSubscriptions
2000000
CY2018Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2018Q2 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6987000
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7347000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6987000
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7347000
CY2018Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
14223000
CY2017Q4 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13790000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26275000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27033000
CY2018Q4 us-gaap Labor And Related Expense
LaborAndRelatedExpense
5985000
CY2017Q4 us-gaap Labor And Related Expense
LaborAndRelatedExpense
5888000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
11932000
us-gaap Labor And Related Expense
LaborAndRelatedExpense
11652000
CY2018Q4 us-gaap Supplies Expense
SuppliesExpense
459000
CY2017Q4 us-gaap Supplies Expense
SuppliesExpense
488000
us-gaap Supplies Expense
SuppliesExpense
869000
us-gaap Supplies Expense
SuppliesExpense
913000
CY2018Q4 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1239000
CY2017Q4 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
1145000
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
2513000
us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
2587000
CY2018Q4 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
169000
CY2017Q4 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
160000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
306000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
314000
CY2018Q4 ssy Health Care Organization Medicare And Medicaid Electronic Health Records Incentives Gain Loss
HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss
0
CY2017Q4 ssy Health Care Organization Medicare And Medicaid Electronic Health Records Incentives Gain Loss
HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss
4000
ssy Health Care Organization Medicare And Medicaid Electronic Health Records Incentives Gain Loss
HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss
0
ssy Health Care Organization Medicare And Medicaid Electronic Health Records Incentives Gain Loss
HealthCareOrganizationMedicareAndMedicaidElectronicHealthRecordsIncentivesGainLoss
21000
CY2018Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
431000
CY2017Q4 ssy Disposal Group Including Discontinued Operation Revenue Net Of Expenses
DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses
6000
CY2017Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
439000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
849000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
868000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-37000
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-80000
us-gaap Operating Income Loss
OperatingIncomeLoss
-795000
us-gaap Operating Income Loss
OperatingIncomeLoss
-179000
CY2018Q4 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
452000
CY2017Q4 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
-4000
us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
454000
CY2018Q4 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0
CY2017Q4 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
944000
CY2018Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2017Q4 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-238000
CY2018Q4 us-gaap Interest Expense
InterestExpense
61000
CY2017Q4 us-gaap Interest Expense
InterestExpense
119000
us-gaap Interest Expense
InterestExpense
122000
us-gaap Interest Expense
InterestExpense
246000
CY2018Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
354000
CY2017Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
503000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-463000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
279000
CY2018Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-296000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-296000
CY2018Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
354000
CY2017Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
799000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-463000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
575000
CY2018Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-49000
CY2017Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-73000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-112000
us-gaap Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
-126000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
305000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
726000
us-gaap Net Income Loss
NetIncomeLoss
-575000
us-gaap Net Income Loss
NetIncomeLoss
449000
CY2018Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2017Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-575000
CY2018Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.05
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.06
CY2017Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.09
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.06
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.06
CY2018Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
CY2017Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
CY2018Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
CY2018Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.04
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.05
CY2018Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7271000
CY2017Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8688000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2946000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-517000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-6730000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-130000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7535000
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10494000
us-gaap Interest Paid Net
InterestPaidNet
109000
us-gaap Interest Paid Net
InterestPaidNet
218000
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.02
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
-0.01
CY2018Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
CY2017Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.02
us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
-0.01
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7309000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9125000
CY2018Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7278000
CY2017Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8758000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7309000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9196000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
265000
ssy Payments To Acquire Property Plant And Equipment Continuing Operations
PaymentsToAcquirePropertyPlantAndEquipmentContinuingOperations
1072000
us-gaap Proceeds From Sale Of Other Assets1
ProceedsFromSaleOfOtherAssets1
937000
us-gaap Proceeds From Sale Of Other Assets1
ProceedsFromSaleOfOtherAssets1
2000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1070000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
3784000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
379000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
176000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 2. &#8211; Business Operations</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Business Operations</font></p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SunLink Health Systems, Inc., through subsidiaries, owns businesses which provide healthcare products and services in certain markets in the southeastern United States. Unless the context indicates otherwise, all references to &#8220;SunLink,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; &#8220;us&#8221; and the &#8220;Company&#8221; refer to SunLink Health Systems, Inc. and our consolidated subsidiaries. References to our specific operations refer to operations conducted through our subsidiaries and references to &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; and &#8220;us&#8221; in such context refer to the operations of our subsidiaries. Our business is composed of two business segments, the Healthcare Services segment and the Pharmacy segment. Our Healthcare Services segment subsidiaries own and operate an 84- bed community hospital and a 66- bed nursing home in Mississippi, a 100- bed nursing home in Georgia, an IT service company based in Georgia, and healthcare facilities, which are leased to third parties. Our Pharmacy segment subsidiary operates a pharmacy business in Louisiana with four service lines.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The business strategy of SunLink is to focus its efforts on improving the operations and expanding the services and profitability of its existing Healthcare Services and Pharmacy businesses while seeking to sell certain of its subsidiaries&#8217; underperforming assets. The Company is also investing in certain upgrades and improvements to certain of its Healthcare Services and Pharmacy businesses.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has used a portion of the cash proceeds from recent dispositions of assets to pay down debt and certain other liabilities, and to repurchase common shares, including in tender offers completed in February and December 2017, and open market repurchases of its common shares, and to make improvements to its Healthcare Services businesses. The Company may also use existing cash, as well as any net proceeds from future dispositions, if any, to prepay debts, return capital to shareholders including through potential public or private purchases of shares, improve its existing businesses, make selective acquisitions of Healthcare Services and Pharmacy businesses and for other general corporate purposes. There is no assurance that any further dispositions will be authorized by the Company&#8217;s Board of Directors or, if authorized, that any such transactions will be completed or, if completed, will result in net cash proceeds to the Company on a before or after tax basis. The Company considers the disposition of business segments, facilities and operations based on a variety of factors in addition to under-performance, including asset values, return on investments, competition from existing and potential competitors, capital improvement needs, the prevailing reimbursement environment under various Federal and state programs (e.g., Medicare and Medicaid) and private payors, and other corporate objectives. The Company believes certain facilities in its Healthcare Services segment as well as its Pharmacy segment continue to under-perform, and the Company has engaged advisors to assist it in evaluating the possible sale of its Pharmacy business lines.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:4.25%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has repurchased 359,959&nbsp;&nbsp;common shares pursuant to a stock repurchase program announced on November 29, 2018, which authorizes the repurchase of a total of 750,000 common shares.&nbsp;&nbsp; </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A subsidiary of the Company has received an indication of interest to purchase one of the Company&#8217;s nursing homes for approximately $7,300 and, on August&#160;29, 2018, entered into a non-binding letter of intent (&#8220;LOI&#8221;) and exclusivity agreement with a potential buyer. The non-binding LOI provides that any transaction will be subject to various terms and conditions (which are currently being negotiated), including reaching final agreement on a contract, satisfactory due diligence and other matters. The Company believes it more likely than not given the present state of negotiations that the transaction will be consummated in the third fiscal quarter at or about the $7,300 offered price but a number of issues remain to be resolved. Accordingly, there can be no assurance that a transaction will in fact be completed on any terms or at any specific price. <font style="Background-color:#FFFFFF;color:#000000;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>&#160; </p>
us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Note 12. &#8211; Economic Damages Claim</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.25%;"><font style="font-weight:normal;">The Pharmacy Segment subsidiary asserted claims for economic damages in connection with the Deepwater Horizon Settlement Program related to the event which occurred in 2010.&nbsp;&nbsp;In January 2018, these claims were settled and payments of approximately $944 (net of costs and attorneys&#8217; fees) were received. The net settlements are recognized as a gain in the Condensed Consolidated Statements of Operations and Comprehensive Earnings (Loss) for the three and six months ended December 31, 2017.</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
CY2018Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
529000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2018Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
750000
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
359959
CY2018Q4 ssy Disposal Group Including Discontinued Operation Revenue Net Of Expenses
DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses
7000
ssy Disposal Group Including Discontinued Operation Revenue Net Of Expenses
DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses
13000
CY2017 us-gaap Operating Expenses
OperatingExpenses
57360000
ssy Disposal Group Including Discontinued Operation Revenue Net Of Expenses
DisposalGroupIncludingDiscontinuedOperationRevenueNetOfExpenses
-6000
CY2018Q4 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-49000
CY2017Q4 us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-73000
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-112000
us-gaap Discontinued Operation Income Loss From Discontinued Operation Before Income Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax
-126000
CY2018Q4 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0
CY2017Q4 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0
us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
0
CY2018Q4 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
300000
CY2018Q4 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
359959
CY2018Q4 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
450000
CY2018Q4 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
372000
CY2018Q4 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
390041
ssy Share Repurchase Average Price Per Share Paid
ShareRepurchaseAveragePricePerSharePaid
1.03
CY2018Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2017Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52169000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52850000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9550000
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18529000
CY2017 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
19917000
us-gaap Operating Expenses
OperatingExpenses
27212000
CY2018 us-gaap Operating Expenses
OperatingExpenses
54163000
CY2018Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
5967000
CY2018Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
5352000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
459000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2018Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
451000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
199000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
408000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
500000
CY2017Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
552000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
451000
CY2018Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
29000
CY2017Q4 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
29000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
58000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
58000
CY2018Q4 us-gaap Capital Lease Obligations
CapitalLeaseObligations
174000
CY2018Q2 us-gaap Capital Lease Obligations
CapitalLeaseObligations
0
CY2018Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
208000
CY2018Q2 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
219000
CY2018Q4 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2017Q4 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-296000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-296000
CY2018Q4 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2017Q4 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8513000
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
0
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
16300000
ssy Net Operating Loss Carry Forwards Expire Period
NetOperatingLossCarryForwardsExpirePeriod
2023 through fiscal 2038
CY2018 ssy Tax Cuts And Jobs Act Change In Tax Rate Discrete Net Tax Benefit
TaxCutsAndJobsActChangeInTaxRateDiscreteNetTaxBenefit
0
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
ssy Tax Cuts And Jobs Act Of2017 Changes In Valuation Allowance Position
TaxCutsAndJobsActOf2017ChangesInValuationAllowancePosition
0
ssy Tax Cuts And Jobs Act Of2017 Provisional Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ProvisionalIncomeTaxExpenseBenefit
0
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Alternative Minimum Tax
DeferredTaxAssetsTaxCreditCarryforwardsAlternativeMinimumTax
296000
ssy Tax Cuts And Jobs Act Of2017 Accounting Complete
TaxCutsAndJobsActOf2017AccountingComplete
true
CY2018Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
238000
CY2017Q4 us-gaap Assets
Assets
28658000
CY2017Q4 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
388000

Files In Submission

Name View Source Status
0001564590-19-002949-index-headers.html Edgar Link pending
0001564590-19-002949-index.html Edgar Link pending
0001564590-19-002949.txt Edgar Link pending
0001564590-19-002949-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ssy-10q_20181231.htm Edgar Link pending
ssy-20181231.xml Edgar Link completed
ssy-20181231.xsd Edgar Link pending
ssy-20181231_cal.xml Edgar Link unprocessable
ssy-20181231_def.xml Edgar Link unprocessable
ssy-20181231_lab.xml Edgar Link unprocessable
ssy-20181231_pre.xml Edgar Link unprocessable
ssy-ex311_9.htm Edgar Link pending
ssy-ex312_8.htm Edgar Link pending
ssy-ex321_7.htm Edgar Link pending
ssy-ex322_6.htm Edgar Link pending